Jan Keltjens currently holds a number of non-executive Board roles, including Chairman of the Boards of JenaValve Technologies and NightBalance He is also associated with the venture capital funds Syncona (London) and INKEF (Amsterdam). He most recently served as chief executive officer of Sapiens Steering Brain Stimulation (acquired by Medtronic in August 2014). Before that he previously was the chairman and chief executive officer of Endosense SA (acquired by St Jude Medical in August 2013), executive chairman of Surpass Medical ltd. (acquired by Stryker Corporation late 2012), as well as president and chief executive officer of AngioDynamics Inc. (ANGO, 2009 – 2011) and CryoCath Technologies Inc. (TSX; CYT, 2007- until its acquisition by Medtronic in 2009). From 2000 to 2007, he served as Worldwide General Manager of Cordis Neurovascular, a Johnson & Johnson company. He joined Cordis in 1995 as Vice President and Managing Director responsible for international manufacturing and distribution operations, as well as research and development. He was promoted to Vice President of European Marketing for all Cordis divisions in 1998 and Vice President of Worldwide Strategic Marketing for Cordis Cardiology, based in Miami, in 1999. Before joining Cordis, Mr. Keltjens led research and development departments at Unilever and was Managing Director of a group of small high tech companies.